Reported 1 day ago
ARS Pharmaceuticals, Inc. (SPRY) presents a bullish thesis highlighted by its position in the epinephrine delivery market with its nasal spray, Neffy, fortified by patents lasting until 2039. While facing legal challenges from Lupin for generic production, the patent litigation has triggered a delay in competition. Neffy’s insurance coverage is increasing, and despite the threat from competitors like Aquestive Therapeutics' Anaphylm, ARS's strong management and market presence suggest a potential for growth, albeit with cautious optimism due to competitive pressures.
Source: YAHOO